FOSUN HEALTH Logo

Alzheimer's Disease & Dementia Treatment

catalogue

Alzheimer's Disease & Dementia Treatment

Alzheimer's Disease & Dementia Treatment

Treatment for Alzheimer's disease does not cure it and does not reverse it. What it does is four things: it modestly improves or stabilises symptoms for some people, it removes what is currently making cognition worse, it keeps the person safe and independent for longer, and it supports the person doing the caring. This page sets out each of those in the order they matter — which is not the order they are usually discussed — including who is eligible for the anti-amyloid antibodies, what the monitoring involves, and why the legal and driving decisions come before the prescription.

What treatment is actually for

Alzheimer's disease is progressive and currently irreversible, and saying that plainly is the precondition for a useful plan. The aim of treatment is not recovery. It is to keep the person functioning, comfortable and safe for as long as possible, and to keep the people around them from being destroyed in the process.

That breaks into four parts, and the order below is the order of their actual impact rather than the order in which they are usually raised.

Part What it consists of How much it changes
Removing what worsens cognition Stopping or substituting medicines with anticholinergic and sedative effects; treating hearing loss, sleep apnoea, pain, constipation, delirium, depression and anxiety Usually the largest and fastest effect, and usually the last thing considered. It is reversible by subtraction
The day, the home and safety Structure, cues and simplification; occupational therapy assessment of the home; driving assessment; arrangements for money This is what preserves independence rather than removing it, and it is measurable in falls, admissions and years at home
The caregiver Information, training, respite, and their own health watched as part of the plan The strongest predictor of whether a person stays at home is not their cognition; it is whether the caregiver can continue
The medicines Cholinesterase inhibitors, memantine, and for a narrow group the anti-amyloid antibodies; medicines for behaviour used rarely and briefly Real but modest on average in the symptomatic drugs; a small average slowing over about eighteen months in the antibody group. Neither is a cure or a reversal

Two framing points prevent most of the disappointment that follows a diagnosis. First, a modest average effect is not nothing — it is a real chance of a period of stability, and it is worth having while the rest of the plan is put in place. Second, the medicine is the part that gets discussed and the other three are the parts that get done, and that inversion is the most common failure in the care of this disease.

The symptomatic medicines, and what modest means

Two classes are in use for Alzheimer's disease itself, and both are symptomatic: they affect the expression of the disease rather than its course. Prescribing is individual, based on stage, on what else the person takes, and on what they and their family want from the medicine.

Medicine Where it is used What to watch and what to expect
Donepezil Mild to moderate Alzheimer's disease; widely used and available in several formulations Once daily. Nausea, vivid dreams and a slow heart rate are among the effects that lead to review; insomnia is commoner if it is taken late in the day
Rivastigmine Mild to moderate Alzheimer's disease, and Parkinson's disease dementia; available as a patch as well as by mouth The patch reduces the gastrointestinal effects and is useful where swallowing or adherence is an issue. Skin reaction under the patch is common and is managed by rotating sites
Galantamine Mild to moderate Alzheimer's disease Taken with food; gastrointestinal effects are the commonest reason for review. Dose is built up rather than started at target
Memantine Moderate to severe disease, alone or added to a cholinesterase inhibitor Generally better tolerated than the cholinesterase inhibitors. Dizziness and constipation occur; dose is adjusted in significant renal impairment
Medicines for behaviour Only where non-drug measures have failed and where there is a risk of harm Used at low dose, for a defined period, with a date to stop. In Lewy body disease, antipsychotics can cause severe and occasionally irreversible worsening and are a last resort

What modest means in practice: the average difference on cognitive and functional rating scales is small, not everyone responds, and the benefit is in stabilisation or slowed decline rather than in recovery. That being said, a medicine that buys a period at the current level of function is worth having, and the decision to continue or stop one should be made deliberately — a review of the person's function at intervals, and a trial off the medicine at the point where the disease has clearly moved past the stage it was helping.

Medicines are also where the harm can come from. Anticholinergics, benzodiazepines and sedating antihistamines worsen cognition directly; antipsychotics carry a real risk in dementia generally and a severe one in Lewy body disease; and polypharmacy is the rule rather than the exception in a person who has accumulated several prescribers. A medicines review is not an optional extra in this disease; it is the single highest-yield intervention available.

Anti-amyloid antibodies: eligibility and monitoring

A new class of treatment has arrived, and it deserves an unexaggerated description. Anti-amyloid monoclonal antibodies bind to amyloid and remove it from the brain. In the trials that led to approval, they produced a small average slowing of decline measured on composite rating scales over about eighteen months, in people with confirmed amyloid pathology at the mild cognitive impairment or mild dementia stage. They did not restore function, they did not stop the disease, and the difference, while statistically real, is of a size that many people would not notice in themselves.

Element What it means in practice
Confirmed amyloid pathology Required, by PET or by cerebrospinal fluid testing. A clinical diagnosis alone is not sufficient, and this is now one of the main reasons biomarker testing is performed
Stage Mild cognitive impairment or mild dementia due to Alzheimer's. Moderate and severe disease are outside the studied population
Imaging exclusions Extensive microhaemorrhages, superficial siderosis, or findings that would make the monitoring uninterpretable generally exclude treatment
APOE genotype Assessed because carrying two copies of the ε4 allele substantially raises the risk of the main complication, and it is part of the risk conversation rather than an automatic exclusion
The infusions Given intravenously at intervals over months, in a unit that can manage an infusion reaction and that can arrange the monitoring scans
MRI monitoring for ARIA Scheduled scans, most frequent in the early months. Most ARIA is found on a scan rather than through symptoms; most resolves on holding or stopping treatment; a minority is symptomatic
Anticoagulation Anticoagulant use is a significant consideration and often a reason not to proceed; where it can be safely managed, that is decided case by case
Availability and cost Regulatory status, availability and cost differ substantially between countries, and that is part of the discussion rather than a footnote to it

The honest shape of the decision is this: a small average slowing, in exchange for a treatment burden of regular infusions and repeated scans, a real monitoring requirement, and an out-of-pocket cost that is considerable where it is not covered. For some families that trade is clearly worth making; for many it is not. It is a decision that belongs to the person and their family after the numbers have been put on the table, not one to be made from a press release. Eligibility is established by a specialist after the workup, and the diagnosis page sets out what that workup contains.

The things making it worse, which are treatable

This is the section that most often produces the largest and quickest improvement, and it is the one most often skipped. The person in front of you has a neurodegenerative disease and a set of things currently reducing how well their brain works. The second of those is where the leverage is.

Contributor Why it matters here What is done
Anticholinergic and sedative medicines Common among bladder medicines, older antihistamines, some anti-nausea and anti-vertigo drugs, tricyclic antidepressants and sedatives; they directly impair attention and memory A review that calculates the burden and substitutes where a safer alternative exists. The improvement over weeks is often the proof
Hearing loss It produces apparent confusion and withdrawal, adds to cognitive load continuously, and is itself associated with faster decline Hearing testing and hearing aids, with the family told to check they are worn and that they fit
Sleep apnoea Fragmented sleep drives inattention, daytime sleepiness and mood change, and adds vascular injury A sleep study where snoring or witnessed apnoea is present, and treatment of what is found
Pain and constipation Both present as agitation and as apparent confusion in someone who cannot report them Asked about directly and treated. Pain assessment in someone who cannot localise it is a skill, not an afterthought
Delirium and infection A urinary or chest infection produces a step down that is attributed to the dementia and left untreated Looked for in any sudden change, and treated. The threshold for investigating is low because the cost of missing it is high
Depression and anxiety Both are common, both worsen cognition, both are treatable, and both are frequently missed because they are assumed to be a reaction to the diagnosis Treated on their own terms, with the cognitive testing repeated afterwards
Vascular risk Hypertension, diabetes, smoking and atrial fibrillation add a second pathology on top of the first, and mixed disease is common Treated as a separate and active target. It is one of the few areas where treatment changes the trajectory rather than the symptoms

None of this is alternative medicine and none of it is a substitute for the diagnosis. It is the ordinary clinical work that gets left undone because everyone is looking at the scan.

Daily life: structure, cues and what still works

The part of management that families can act on tomorrow is not a prescription. It is the shape of the day, and the principle behind it is simple: reduce the number of decisions, and increase the number of cues.

Predictability is the single most useful quality an environment can have. Regular times for waking, meals, activity and sleep; the same route, the same room, the same sequence; fewer choices at each step — two outfits rather than a wardrobe, one plate rather than a menu. Choices that were once effortless become effortful, and the person conserves what they have by avoiding them, which reads as apathy.

Cues work because they move the task from recall to recognition. Labels on cupboards, photographs on doors, a clock that shows the day and date rather than only the time, a written list by the telephone, a pill organiser filled by someone else, and objects left where they are used rather than put away. Recognition survives much longer than recall, and that difference is the whole basis of the technique.

Task simplification is the other half: break the task into steps, do it alongside rather than for the person, and stop at the point of frustration rather than pushing through it. What the person can still do should be left to them for as long as possible — doing something for someone because it is faster is the fastest way to lose an ability that was still there.

And what still works should be used deliberately: music, singing and rhythm, familiar routines and objects, touch, walking, and the company of one calm person rather than several. These are not consolations. They are the channels that remain open, and a care plan that ignores them is poorer than it needs to be.

Safety: driving, wandering, money and the kitchen

These four carry more practical consequence than anything else in the illness, and all of them are better settled early than late. The reason is that each one becomes harder to settle as capacity declines, and each one is more damaging when it is settled in a crisis.

Area What to assess What to arrange
Driving Not route memory alone: reaction time, divided attention, distance and gap judgement, and response to the unexpected A formal driving assessment, which is objective and takes the argument out of the family. Arrange transport alternatives before driving stops. Notification duties vary by jurisdiction and belong to the driver
Wandering and getting lost Whether the person has already gone out and become lost, and whether they leave at particular times or for particular reasons Identification worn or carried, a location device if the family wants one, door alerts, and registration with local services where they exist. Leaving is usually purposeful rather than random, and finding the purpose helps
Money and documents Whether bills are unpaid, whether unusual purchases have appeared, and whether anyone has begun helping without being asked Direct debits for essentials, reduced access to large sums, a trusted contact at the bank, and a named person on the accounts. Scam targeting of people with cognitive impairment is common and it is worth naming to the family
The kitchen and the home The hob, the kettle, the toaster, the stairs, the bathroom, the tools and the medicines in the house An occupational therapy assessment of the home, done before the first fall rather than after it. Isolate the hob, remove the kettle lead, fit grab rails, improve lighting, and lock away medicines and tools

The one that families find hardest is driving, and it is worth saying why it is not negotiable: the risk is not only to the driver. A formal assessment, arranged early, with alternatives already in place, is what preserves the person's dignity and the family's relationship rather than damaging either.

The caregiver, and the crisis that can be predicted

The strongest single predictor of whether a person with dementia remains at home is not their score on any test. It is whether the person caring for them can continue. That makes the caregiver part of the clinical plan rather than an adjunct to it, and it makes their health something to be asked about at every review.

The predictable crisis has a shape, and it is worth naming because it is so often experienced as a personal failure: the caregiver's own sleep breaks down, their health appointments are missed, a job is given up or reduced, resentments accumulate, and then an acute illness in the caregiver — or a fall, or an infection in the person — converts a stable arrangement into an emergency admission. Almost every element of that sequence was visible months earlier.

Element What it means
Information and training Knowing what the disease does, what a behaviour means, and what to do when it happens — taught rather than discovered
Respite arranged in advance Regular hours of relief built into the week from the beginning, not requested at the point of collapse
The caregiver's own health Their appointments kept, their medicines taken, their sleep protected — asked about at each review and recorded
A named contact and a plan for illness Who takes over if the caregiver is unwell, written down, and known to the rest of the family
Money and legal authority Sorted while the person can still sign, so that the caregiver is not applying for authority in the middle of a crisis
Support that names the emotion Grief, guilt and resentment in the course of this illness are ordinary. Support groups and counselling are treatment, not indulgence

One thing to state plainly: needing help, and reaching the point where care at home is no longer possible, is not a failure. It is the expected course of a progressive disease, and planning for it is what makes it bearable rather than catastrophic. The living-with-dementia page sets out how that plan is written down.

Frequently Asked Questions

Do the medicines actually help?

They help modestly and they help symptoms, and those two qualifications matter. Cholinesterase inhibitors produce a small average improvement or a period of stabilisation in cognition and daily function in mild to moderate Alzheimer's; memantine is used in moderate to severe disease, sometimes alongside them. The average effect is small, individuals vary, and none of them stops or reverses the underlying disease. The honest framing is that they buy time at the current level of function for some people, and that stopping them should be a considered decision rather than a default. The parts of management that reliably change daily life are the medication review, treating hearing and sleep, structuring the day, and supporting the caregiver — and those are the parts most often left undone.

Who is eligible for the anti-amyloid antibodies?

A narrow group, and the narrowness is the point. Eligibility requires confirmed amyloid pathology, disease at the mild cognitive impairment or mild dementia stage, brain imaging without findings that exclude treatment, and usually an assessment of APOE genotype because it modifies the risk of the main complication. People with a history of certain bleeds, with extensive microhaemorrhages on imaging, or with anticoagulation that cannot be managed are generally not candidates. Eligibility is established by a specialist after the workup, not assumed from a diagnosis, and the decision is made jointly with the person and the family after the monitoring schedule has been explained.

What is ARIA, and does it mean the treatment is dangerous?

ARIA stands for amyloid-related imaging abnormalities: changes seen on MRI during antibody treatment, either swelling in the brain substance or small bleeds on its surface. Most episodes are detected on a monitoring scan rather than because of symptoms, and most resolve on holding or stopping the infusion; a minority are symptomatic and a small number are serious. It is the reason the treatment requires a defined schedule of MRI scans, particularly in the first months, and the reason eligibility assessment includes the imaging findings and the APOE genotype. It is a real risk that is managed by monitoring rather than a reason to dismiss the treatment, and it belongs in the conversation before the decision rather than after it.

Should we stop driving?

It should be assessed, not assumed, and the timing is earlier than most families expect. The relevant skills are not just remembering a route: they are reaction time, divided attention, judging distance and gap, and responding to the unexpected — and those decline before the person notices. A formal driving assessment is the right instrument, because it is objective and it takes the argument out of the family. Two practical points: the legal obligation to notify a licensing authority varies by jurisdiction and is the driver's own responsibility, and continuing to drive after a licence should have been surrendered can void insurance. Arranging alternatives before driving stops is what preserves independence rather than removing it.

Get a plan written down, not just a diagnosis

Send the diagnosis and clinic letters, the current medicines list including anything bought over the counter, any cognitive scores with their dates, and imaging and blood test results. Our team will return a written opinion on what the workup supports, which reversible contributors remain unaddressed, whether any antibody question is live in your case, and what can be arranged before any travel is discussed.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*